InVitria Manufacturing Facility Achieves ISO 9001:2000 CertificationAchievement reflects InVitria’s commitment to exceeding customer requirements for product quality and consistency. Fort Collins, CO, September 10, 2009 – InVitria announced that its manufacturing facility achieved the International Organization of Standardization (ISO) 9001:2000 Certification. This level of certification recognizes the facility’s establishment of a Quality Management System that focuses on exceeding customer expectations. Ultimately, it provides credibility to the processes employed to manufacture InVitria’s high performance, well defined and regulatory friendly cell culture media supplements. “Achieving ISO 9001:2000 Certification demonstrates InVitria’s commitment to quality across the organization,” said Greg Unruh, Vice President for Manufacturing. “This certification was a team effort with every employee contributing to the successful implementation of our Quality Management System. Knowing that our facility has reached this level of standardization helps to validate the integrity of our products and builds upon our desire to exceed customer expectations,” said Unruh. InVitria’s manufacturing facility produces animal component free cell culture media supplements that optimize performance of CHO, Hybridoma, VERO, stem cells and primary cells. InVitria supplies cell culture media supplements to leading biopharmaceutical, biomanufacturing and stem cell and regenerative medicine companies. About InVitria (www.InVitria.com) InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics. For more information about InVitria’s product line, contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call 1-800-916-8311.
|
-
Blog: The Cell Culture Dish
Strategies for Improving Viral Yield in Vaccine Manufacturing
A recent article in Pharma Times titled "US biopharma: nearly 300 vaccines in R&D," points out that there are currently 300 vaccines either in clinical studies or under review by the Food and Drug Administration (FDA). While not all vaccines are cell culture derived vaccines, it does indicate that a large number of cell culture based viral vaccines are in the pipeline and that perhaps viral vaccine manufacturing should be examined. One area under consideration is how to improve viral yield so that vaccines can be made at lower cost ... Read More
-
Latest News
InVitria Attends the 13th Bi-Annual Cell Culture Engineering Conference
March 29, 2012 - InVitria is attending the 13th Bi-Annual Cell Culture Engineering Conference in Scottsdale, Arizona April 22nd through the 27th. This event is an invitation only conference that includes approximately 350 of the world's top academic and industry cell culture scientists. Topics at the conference range from fundamental science to the engineering challenges of cell culture process development.... read more
